Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma

被引:36
作者
Cohen, Yoram [4 ]
Merhavi-Shoharn, Efrat [2 ,3 ]
Avraharn, Revital B. [2 ,6 ]
Frenkel, Shahar [5 ]
Pe'er, Jacob [5 ]
Goldenberg-Cohen, Nitza [1 ,2 ,6 ]
机构
[1] Schneider Childrens Med Ctr, Dept Ophthalmol, Pediat Unit, IL-49202 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Felsenstein Med Res Ctr, Krieger Eye Res Lab, IL-49100 Petah Tiqwa, Israel
[3] Bar Ilan Univ, Fac Life Sci, Mina & Everard Goodman, Ramat Gan, Israel
[4] Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Dept Gynecol, IL-52621 Tel Hashomer, Israel
[5] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel
[6] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
关键词
retinoblastoma; BRAF mutations; RASSF1A; epigenetic silencing; tumor suppressor genes; methylation status; CIMP; CpG island methylator phenotype;
D O I
10.1016/j.exer.2007.10.010
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Epigenetic silencing of tumor suppressor genes by methylation of discrete regions of the CpG islands is a major mechanism underlying tumorigenesis. Methylation of at least three of five specific genes may represent a distinct trait, termed the CpG island methylator phenotype (CIMP). Positive CIMP is associated with BRAF mutations. The present study sought to investigate the presence of BRAF mutations in human retinoblastoma and the role of epigenetic silencing of multiple tumor suppression genes in a search for methylation phenotype. Twenty-five archival retinoblastoma samples were analyzed for BRAF mutations with polymerase chain reaction, Mutector(R) assay, and direct sequencing. Nineteen samples were also analyzed for the promoter methylation status of eight candidate cancer-related genes using real-time quantitative methylation-specific polymerase chain reaction after sodium bisultite modification. The CIMP status was determined. No BRAF mutations were found. The frequencies of cancer-related gene methylation were as follows: 89% for RASSF1A, 52% for NEUROG1, 5% for DAP-kinase, RUNX3 and CACNA1G, and 0 for RAR-beta 2, SOCS-1 and IGF-2. The lack of BRAF mutations in retinoblastoma is in accord with the negative CIMP status and the high hypermethylation rate for RASSF1A. The high methylation status for NEUROG1 may point. to an alternative pathway in the development and progression of retinoblastoma, but further studies are needed. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 41 条
[21]   Methylation status of RB1 promoter in Indian retinoblastoma patients [J].
Joseph, B ;
Mamatha, G ;
Raman, G ;
Shanmugam, MP ;
Kumaramanickavel, G .
CANCER BIOLOGY & THERAPY, 2004, 3 (02) :184-187
[22]  
KOHONENCORISH MR, 2007, ONCOGENE
[23]   HUMAN RETINOBLASTOMA SUSCEPTIBILITY GENE - CLONING, IDENTIFICATION, AND SEQUENCE [J].
LEE, WH ;
BOOKSTEIN, R ;
HONG, F ;
YOUNG, LJ ;
SHEW, JY ;
LEE, EYHP .
SCIENCE, 1987, 235 (4794) :1394-1399
[24]   Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome [J].
Lillington, DM ;
Kingston, JE ;
Coen, PG ;
Price, E ;
Hungerford, J ;
Domizio, P ;
Young, BD ;
Onadim, Z .
GENES CHROMOSOMES & CANCER, 2003, 36 (02) :121-128
[25]   Retinoblastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project [J].
MacCarthy, A. ;
Draper, G. J. ;
Steliarova-Foucher, Eva ;
Kingston, J. E. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (13) :2092-2102
[26]  
Merbs SL, 1999, INVEST OPHTH VIS SCI, V40, P779
[27]   Promoter methylation status of multiple genes in uveal melanoma [J].
Merhavi, Efrat ;
Cohen, Yoram ;
Avraham, Bat Chen R. ;
Frenkel, Shahar ;
Chowers, Itay ;
Pe'er, Jacob ;
Goldenberg-Cohen, Nitza .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (10) :4403-4406
[28]  
MICHALOGLOU C, 2007, BRAFE600 BENIGN MALI
[29]  
MINOO P, 2007, J PATHOL
[30]   Second primary tumors in hereditary retinoblastoma: A register-based study, 1945-1997 - Is there an age effect on radiation-related risk? [J].
Moll, AC ;
Imhof, SM ;
Schouten-VanMeeteren, YN ;
Kuik, DJ ;
Hofman, P ;
Boers, M .
OPHTHALMOLOGY, 2001, 108 (06) :1109-1114